Good morning!

Markets are already heating up again to start the week (are they ever down on Monday anymore?), so I hope you are in for a great week of trading!

Small-cap stocks have been especially hot lately. 🔥

In fact, just last week, a couple of my alerts jumped 40% and 60% after I told you about them.

Things can move very quickly, so I always suggest having a good game plan before you make a trade, and don’t get too greedy by holding out for “home runs” all of the time.

I don’t know about you, but I always think a nice 5-10% gain on a trade is a perfectly good thing to walk away with if I can get it.

Today, I want to talk about a very interesting stock that you’ve likely never heard of.

This Company just went public a few months ago with an ambitious goal in mind – to reverse the aging process.

If they are successful, I can only imagine how big the market could be for this.

Pull up Telomir Pharmaceuticals, Inc. (TELO) on your platform right now, and let me show you why it is so important this morning.

As I said, this stock is a recent IPO.

It is a fairly “low float” stock, which means that it can make some very big moves (in either direction) because there are not many shares in the way.

Not a lot of people I know have ever heard of TELO, and as you can see below on the daily chart, since its IPO, when volume picks up, the price has really been able to surge higher.

Just for perspective, the days after the IPO led to more than a 300% move from the lows.

Last month, TELO rallied 80% from the lows over a few days.

Of course there are never guarantees in trading, but if you see the volume spike I circled above (which was Friday last week), I think we could be setting up for something big once again.

I also see a strong “wedge pattern” forming right now, which is a series of lower highs and higher lows.

I have found that when a stock finally breaks out of that wedge (in either direction), the moves can be massive.

Looking at this, I see two important price levels to watch right now.

The first would be the lower end of the wedge, which would be a closing price under $5.  If that happens, then I’d say this play didn’t work, and I would walk away.

On the other hand, if things go my way, I would look at a closing price above $7.50 to establish a new breakout to the upside for TELO.

If you have been watching some of the recent IPOs with low floats, you know why I think this is such a good opportunity to watch right now.

Some of those stocks have made incredible gains lately, and if we’re lucky, I think TELO could follow right in those footsteps.

Keeping a close eye on TELO all day today is very important!

Telomir Pharmaceuticals, Inc. (TELO) is a pre-clinical pharmaceutical company         focused on the development and commercialization of the first small molecule targeted at lengthening telomeres.

If you’re familiar at all with longevity research, you know that telomere breakdown is considered a primary cause of human aging.

As the New York Times reported last week in an article titled “Why Do We Age?”, “as we age, telomere shortening becomes a problem, particularly in stem cells, which the body uses to replenish skin, blood and other tissues.”

TELO believes that its lead molecule, Telomir-1, could “delay, prevent, or even reverse age-related decline” by protecting and lengthening telomeres.

Read that sentence again and let me know if you think that could generate some revenue. 

Investors clearly think so…

Founded in August 2021 and IPO’ing in February of this year, the Baltimore-based company already boasts an impressive $200 million market cap.

The science behind Telomir-1 gets complicated, but the basic idea is that, as we age, high levels of certain metals — especially iron, copper, and zinc — cause enzyme activity that contributes to oxidation and inflammation.

In turn, this can lead to diseases such as hemochromatosis as well as a broad range of cancers. It also leads to the shortening of telomeres.

Telomir-1 is a novel treatment that selectively binds some of those metals, returning them to homeostasis in order to regulate enzymatic activity.

In theory, this could turn off an underlying cause of cancer development in growth.

In March, TELO announced “in silico” evidence powered by AI-driven models that indicated that “the mechanism of action of Telomir-1 has the potential to reverse age-related conditions such as osteoarthritis by lengthening DNA’s protective telomere caps.”

Later that month, the company unveiled a three-to-six month study of Telomir-1 to treat osteoporosis in canines that could provide the basis for an Investigation New Drug Application to the FDA.

In April, TELO revealed company data at the National Press Club that showed that Telomir-1 caused telomeres to lengthen in vitro in human cells and telomerase activity to increase by 40%.

TELO also said it expects to begin clinical trials for osteoarthritis in humans in the second and third quarter of 2025.

Impressively, TELO has brought on Michael F. Roizen, MD as a Special Advisor on Age Reversal for the company.

Previously, Dr. Roizen was the Chief Wellness Officer of the Cleveland Clinic. He has published four #1 New York Times best-selling books that have been translated into 44 languages. 

He has also authored more than 195 peer-reviewed scientific papers and has received 14 U.S. patents. 

Dr. Roizen says that “TELOMIR-1 may be a key to telomere regeneration, and subsequent benefits that have the effect of age reversing, by enabling the ability to produce more stem cells, resulting in an individual’s ability to repair oneself with oral medication. 

“I believe Telomir’s technology has tremendous potential to delay, prevent, or even reverse age-related decline. I’m eager to work with the team to make telomere therapies a reality.”

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: There is a very special opportunity with TELO right now.  This potentially game-changing biotech company might be on the verge of something great right now, so spend time learning all you can about it.

Make sure you have TELO on the top of your watchlist as you start the week!

To Your Success,

Jeff Bishop

P.S. ⏰ Make sure set a reminder to join me and over 1000 traders at 9am EST in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

⏰⏰ Make that a DOUBLE reminder, because you’ll want to join me again at 2pm EST this afternoon for an exclusive live trading session where I will show you in detail how I use my “Gamma Trigger” system to find breakout trades.

We have a huge day of trading ahead of us!



*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twelve thousand dollars (cash) from Legends Media for advertising Telomir Pharmaceuticals, Inc for a one-day marketing program on may 28, 2024. This amount was paid by someone else not connected to Telomir Pharmaceuticals, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Telomir Pharmaceuticals, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.